Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 21:6:19690.
doi: 10.1038/srep19690.

Early Results of Clinical Application of Autologous Whole Bone Marrow Stem Cell Transplantation for Critical Limb Ischemia with Buerger's Disease

Affiliations

Early Results of Clinical Application of Autologous Whole Bone Marrow Stem Cell Transplantation for Critical Limb Ischemia with Buerger's Disease

Seon-Hee Heo et al. Sci Rep. .

Abstract

Our goal was to evaluate early results of the clinical application of autologous whole bone marrow stem cell transplantation (AWBMSCT) for critical limb ischemia (CLI) in patients with Buerger's disease. We retrospectively analyzed the data of 58 limbs of 37 patients (mean age, 43.0 years; range, 28-63 years; male, 91.9%) with Buerger's disease with CLI who were treated with AWBMSCT from March 2013 to December 2014. We analyzed Rutherford category, pain score, pain-free walking time (PFWT), total walking time (TWT), ankle brachial pressure index (ABPI), and toe brachial pressure index (TBPI), and investigated wound healing and occurrence of unplanned amputations. The mean follow-up duration was 11.9 ± 7.2 months (range, 0.9-23.9 months) and 100%, 72.4%, and 74.1% of patients were available to follow-up 1, 3 and 6 months after AWBMST, respectively. At 6 months, patients demonstrated significant improvements in Rutherford category (P < 0.0001), pain score (P < 0.0001), PFWT (P < 0.0001) and TBPI (P < 0.0001). ABPI was increased compared to baseline, but the difference was not significant. A total of 76.5% ischemic wounds achieved complete or improved healing. AWBMSCT is a safe and effective alternative or adjunctive treatment modality to achieve clinical improvement in patients with CLI.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Serial changes in Rutherford category (0–6) (A) and CLI-free ratio (B) after AWBMSCT (n = 58 at 1 month, n = 42 at 3 months, n = 43 at 6 months). *Represents P < 0.05 compared with baseline data.
Figure 2
Figure 2
Serial changes in pain score (numeric rating scale, NRS) (A) and pain-free walking time (PFWT)(sec) (B) after AWBMSCT (n = 58 at 1 month, n = 42 at 3 months, n = 43 at 6 months). *Represents P < 0.05 compared with data at baseline, Represents P < 0.05 compared with data at 1 month after treatment, Represents P < 0.05 compared with data at 3 months after treatment.
Figure 3
Figure 3
Serial changes in ankle brachial pressure index (ABPI) (A) and toe brachial pressure index (TBPI) (B) after AWBMSCT (n = 58 at 1 month, n = 42 at 3 months, n = 43 at 6 months). *Represents P < 0.05 compared with data at baseline, Represents P < 0.05 compared with data at 1 month after treatment, Represents P < 0.05 compared with data at 3 months after treatment.

References

    1. Rutherford R. B. et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J. Vasc. Surg. 26, 517–538 (1997). - PubMed
    1. Norgren L. et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur. J. Vasc. Endovasc. Surg. 33 Suppl 1, S1–75 (2007). - PubMed
    1. Klein-Weigel P. F. & Richter J. G. Thromboangiitis obliterans (Buerger’s disease). Vasa 43, 337–346 (2014). - PubMed
    1. Paraskevas K. I., Liapis C. D., Briana D. D. & Mikhailidis D. P. Thromboangiitis obliterans (Buerger’s disease): searching for a therapeutic strategy. Angiology 58, 75–84 (2007). - PubMed
    1. Kim A. K. et al. Stem-cell therapy for peripheral arterial occlusive disease. Eur. J. Vasc. Endovasc. Surg. 42, 667–675 (2011). - PubMed

Publication types